AtaiBeckley: Canaccord Raises Target to $17 and Praises Progress in DMT Buccal Film Study!
Reading Time: 3 minutes
The biopharma sector continues to experience steady interest in companies dedicated to developing novel treatments for mental health in the summer of 2026. A key player in this segment is AtaiBeckley (ATAI) . In recent weeks, particularly at the threshold of June to July 2026, company-specific news has intensified. These operational advancements have directly impacted analysts' assessments and define the current market environment for the stock. Central to the interest is the drug candidate VLS-01. Milestone in the Elumina Phase 2 Study ...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
